233 related articles for article (PubMed ID: 19169884)
1. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma.
Brodie SE; Pierre Gobin Y; Dunkel IJ; Kim JW; Abramson DH
Doc Ophthalmol; 2009 Aug; 119(1):13-22. PubMed ID: 19169884
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.
Abramson DH; Dunkel IJ; Brodie SE; Kim JW; Gobin YP
Ophthalmology; 2008 Aug; 115(8):1398-404, 1404.e1. PubMed ID: 18342944
[TBL] [Abstract][Full Text] [Related]
3. Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function.
Abdelhakim AH; Francis JH; Marr BP; Gobin YP; Abramson DH; Brodie SE
Br J Ophthalmol; 2017 May; 101(5):623-628. PubMed ID: 27539090
[TBL] [Abstract][Full Text] [Related]
4. Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.
Rowlands MA; Mondesire-Crump I; Levin A; Mauguen A; Francis JH; Dunkel IJ; Brodie SE; Gobin YP; Abramson DH
PLoS One; 2018; 13(4):e0195395. PubMed ID: 29698399
[TBL] [Abstract][Full Text] [Related]
5. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).
Abramson DH; Dunkel IJ; Brodie SE; Marr B; Gobin YP
Ophthalmology; 2010 Aug; 117(8):1623-9. PubMed ID: 20381868
[TBL] [Abstract][Full Text] [Related]
6. ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma.
Brodie SE; Paulus YM; Patel M; Gobin YP; Dunkel IJ; Marr BP; Abramson DH
Br J Ophthalmol; 2012 Jun; 96(6):877-80. PubMed ID: 22426950
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.
Francis JH; Abramson DH; Gobin YP; Marr BP; Tendler I; Brodie SE; Dunkel IJ
Ophthalmology; 2015 May; 122(5):1016-22. PubMed ID: 25616769
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma.
Muen WJ; Kingston JE; Robertson F; Brew S; Sagoo MS; Reddy MA
Ophthalmology; 2012 Mar; 119(3):611-6. PubMed ID: 22197434
[TBL] [Abstract][Full Text] [Related]
9. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors.
Peterson EC; Elhammady MS; Quintero-Wolfe S; Murray TG; Aziz-Sultan MA
J Neurosurg; 2011 Jun; 114(6):1603-8. PubMed ID: 21294621
[TBL] [Abstract][Full Text] [Related]
10. Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision.
Tsimpida M; Thompson DA; Liasis A; Smith V; Kingston JE; Sagoo MS; Reddy MA
Br J Ophthalmol; 2013 Nov; 97(11):1464-70. PubMed ID: 24037611
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.
Abramson DH; Fabius AW; Francis JH; Marr BP; Dunkel IJ; Brodie SE; Escuder A; Gobin YP
Ophthalmic Genet; 2017; 38(1):16-21. PubMed ID: 28095092
[TBL] [Abstract][Full Text] [Related]
12. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
13. Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience.
Michaels ST; Abruzzo TA; Augsburger JJ; Corrêa ZM; Lane A; Geller JI
J Pediatr Hematol Oncol; 2016 Jan; 38(1):65-9. PubMed ID: 26583615
[TBL] [Abstract][Full Text] [Related]
14. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
Brodie SE; Munier FL; Francis JH; Marr B; Gobin YP; Abramson DH
Doc Ophthalmol; 2013 Feb; 126(1):79-84. PubMed ID: 23143758
[TBL] [Abstract][Full Text] [Related]
15. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.
Daniels AB; Froehler MT; Nunnally AH; Pierce JM; Bozic I; Stone CA; Santapuram PR; Tao YK; Boyd KL; Himmel LE; Chen SC; Du L; Friedman DL; Richmond A
Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):954-964. PubMed ID: 30882851
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Technical and Adjunctive Factors with Quantitative Tumor Reduction in Children Undergoing Selective Ophthalmic Artery Infusion Chemotherapy for Retinoblastoma.
Abruzzo T; Abraham K; Karani KB; Geller JI; Vadivelu S; Racadio JM; Zhang B; Correa ZM
AJNR Am J Neuroradiol; 2021 Jan; 42(2):354-361. PubMed ID: 33361377
[TBL] [Abstract][Full Text] [Related]
17. Non-selectivity of ERG reductions in eyes treated for retinoblastoma.
Liu CY; Jonna G; Francis JH; Marr BP; Abramson DH; Brodie SE
Doc Ophthalmol; 2014 Feb; 128(1):13-23. PubMed ID: 24213436
[TBL] [Abstract][Full Text] [Related]
18. Retinal vascular precipitates during administration of melphalan into the ophthalmic artery.
Superstein R; Lederer D; Dubois J; Hamel P; Carret AS; Callejo S
JAMA Ophthalmol; 2013 Jul; 131(7):963-5. PubMed ID: 23846208
[No Abstract] [Full Text] [Related]
19. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
20. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma.
Reddy MA; Naeem Z; Duncan C; Robertson F; Herod J; Rennie A; Liasis A; Thompson DA; Sagoo M
Br J Ophthalmol; 2017 Dec; 101(12):1704-1708. PubMed ID: 28432112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
